Alzheimer’s Blockbuster Might Spur Investor Bonanza, Higher Medicare Costs

The Alzheimer’s drug data released Tuesday night aren’t only going to be transformative for Biogen which has been struggling to get love from investors after its botched launch of Aduhelm. 

The results are also breathing new life into a class of anti-amyloid drugs that had been partially written off, increasing investor confidence that drugs from Eli Lilly and Roche Holding also deliver positive results.